Terms: = Germ cell tumor AND RPL10, XX-FW83563B9_1, 6134, ENSG00000147403, FLJ27072, DXS648, DXS648E, DKFZp686J1851, P27635, QM, FLJ23544 AND Treatment
35875 results:
1. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
[TBL] [Abstract] [Full Text] [Related]
2. Navigating diagnostic challenges-distinguishing malignant melanoma and clear cell sarcoma of soft tissues: a case report and review of the literature.
Abdouh S; Boujguenna I; Soleh A; Abkari I; Rais H
J Med Case Rep; 2024 May; 18(1):249. PubMed ID: 38755643
[TBL] [Abstract] [Full Text] [Related]
3. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
4. The diagnostic challenge of lack of choline level elevation on 1H-MR spectroscopy in grade II-III gliomas.
Bobek-Billewicz B; Heinze S; Majchrzak K; Mazgaj P; Hebda A
Folia Neuropathol; 2024; 62(1):13-20. PubMed ID: 38741433
[TBL] [Abstract] [Full Text] [Related]
5. Association of 5-aminolevulinic acid fluorescence guided resection with photodynamic therapy in recurrent glioblastoma: a matched cohort study.
da Silva EB; Vasquez MWM; de Almeida Teixeira BC; Neto MC; Sprenger F; Filho JLN; Almeida-Lopes L; Ramina R
Acta Neurochir (Wien); 2024 May; 166(1):212. PubMed ID: 38739282
[TBL] [Abstract] [Full Text] [Related]
6. [Predicting the effectiveness of organ-preserving treatment of choroidal melanoma using optical coherence tomography data].
Stoyukhina AS
Vestn Oftalmol; 2024; 140(2. Vyp. 2):16-20. PubMed ID: 38739126
[TBL] [Abstract] [Full Text] [Related]
7. Repeat Radiosurgery for Sporadic Vestibular Schwannoma After Primary Radiosurgical Failure: An International Multi-institutional Investigation.
Khandalavala KR; Herberg HA; Kay-Rivest E; Moore LS; Yancey KL; Marinelli JP; Lund-Johansen M; Kosaraju N; Lohse CM; Kutz W; Santa Maria PL; Golfinos JG; Kondziolka D; Carlson ML; Tveiten ØV; Link MJ
Otol Neurotol; 2024 Jun; 45(5):587-593. PubMed ID: 38728563
[TBL] [Abstract] [Full Text] [Related]
8. Vaccimel immunization is associated with enhanced response to treatment with anti-PD-1 monoclonal antibodies in cutaneous melanoma patients - a case reports study.
Mordoh J; Schwab E; Bravo AI; Aris M; Barrio MM
Front Immunol; 2024; 15():1354710. PubMed ID: 38726010
[TBL] [Abstract] [Full Text] [Related]
9. Glioma.
Weller M; Wen PY; Chang SM; Dirven L; Lim M; Monje M; Reifenberger G
Nat Rev Dis Primers; 2024 May; 10(1):33. PubMed ID: 38724526
[TBL] [Abstract] [Full Text] [Related]
10. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
Baugh R; Khalique H; Page E; Lei-Rossmann J; Wan PK; Johanssen T; Ebner D; Ansorge O; Seymour LW
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724464
[TBL] [Abstract] [Full Text] [Related]
11. State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.
Schaff LR; Ioannou M; Geurts M; van den Bent MJ; Mellinghoff IK; Schreck KC
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431450. PubMed ID: 38723228
[TBL] [Abstract] [Full Text] [Related]
12. Preoperative peripheral inflammatory markers are predictors of postoperative central diabetes insipidus in craniopharyngioma patients: a retrospective study.
Wang J; Wang G; Cheng L; Zhu H; Wang J; Ding X; Niu H; Zhao K; Shu K
BMC Cancer; 2024 May; 24(1):572. PubMed ID: 38720306
[TBL] [Abstract] [Full Text] [Related]
13. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
[TBL] [Abstract] [Full Text] [Related]
14. Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.
Falkman L; Sundin A; Skogseid B; Botling J; Bernardo Y; Wallin G; Zhang L; Welin S; Lase I; Mollazadegan K; Crona J
Ups J Med Sci; 2024; 129():. PubMed ID: 38716076
[TBL] [Abstract] [Full Text] [Related]
15. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
[TBL] [Abstract] [Full Text] [Related]
16. Altering biomolecular condensates as a potential mechanism that mediates cannabidiol effect on glioblastoma.
Wang LP; Chagas PS; Salles ÉL; Naeini SE; Gouron J; Rogers HM; Khodadadi H; Bhandari B; Alptekin A; Qin X; Vaibhav K; Costigliola V; Hess DC; Dhandapani KM; Arbab AS; Rutkowski MJ; Yu JC; Baban B
Med Oncol; 2024 May; 41(6):140. PubMed ID: 38713310
[TBL] [Abstract] [Full Text] [Related]
17. treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract] [Full Text] [Related]
18. Total hysterectomy versus radical hysterectomy in neuroendocrine cervical cancer: a SEER-database analysis.
Zeng F; Guo P; Xia M; He M
J Cancer Res Clin Oncol; 2024 May; 150(5):236. PubMed ID: 38710946
[TBL] [Abstract] [Full Text] [Related]
19. Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study.
Tometich DB; Geiss C; Maconi ML; Chavez M; Hoogland AI; Li X; Nieves-Lopez A; Rodriguez Y; Bryant C; Brohl AS; Eroglu Z; Markowitz J; Tarhini AA; Hwu P; Khushalani NI; Jim HSL
Support Care Cancer; 2024 May; 32(6):330. PubMed ID: 38709312
[TBL] [Abstract] [Full Text] [Related]
20. VEGFR2 blockade inhibits glioblastoma cell proliferation by enhancing mitochondrial biogenesis.
Guo M; Zhang J; Han J; Hu Y; Ni H; Yuan J; Sun Y; Liu M; Gao L; Liao W; Ma C; Liu Y; Li S; Li N
J Transl Med; 2024 May; 22(1):419. PubMed ID: 38702818
[TBL] [Abstract] [Full Text] [Related]
[Next]
